Lipodystrophy raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-25 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
=== Railway === Several train stations serve Moscow. The city's ten rail terminals (or vokzals) are the following: Belorussky Kazansky Kiyevsky Kursky Leningradsky Paveletsky Rizhsky Savyolovsky Yaroslavsky Vostochny
== Structure == Human and yeast glutathione synthetases are homodimers, meaning they are composed of two identical subunits of itself non-covalently bound to each other. On the other hand, E. coli glutathione synthetase is a homotetramer. Nevertheless, they are part of the ATP-grasp superfamily, which consists of 21 enzymes that contain an ATP-grasp fold. Each subunit interacts with each other through alpha helix and beta sheet hydrogen bonding interactions and contains two domains. One domain facilitates the ATP-grasp mechanism and the other is the catalytic active site for γ-glutamylcysteine. The ATP-grasp fold is conserved within the ATP-grasp superfamily and is characterized by two alpha helices and beta sheets that hold onto the ATP molecule between them. The domain containing the active site exhibits interesting properties of specificity. In contrast to γ-glutamylcysteine synthetase, glutathione synthetase accepts a large variety of glutamyl-modified analogs of γ-glutamylcysteine, but is much more specific for cysteine-modified analogs of γ-glutamylcysteine. Crystalline structures have shown glutathione synthetase bound to GSH, ADP, two magnesium ions, and a sulfate ion. Two magnesium ions function to stabilize the acylphosphate intermediate, facilitate binding of ATP, and activate removal of phosphate group from ATP. Sulfate ion serves as a replacement for inorganic phosphate once the acylphosphate intermediate is formed inside the active site.
When a drug is developed with evidence throughout its history of research to show it is safe and effective for the intended use in the United States, the company can file an application – the New Drug Application (NDA) – to have the drug commercialized and available for clinical application. NDA status enables the FDA to examine all submitted data on the drug to reach a decision on whether to approve or not approve the drug candidate based on its safety, specificity of effect, and efficacy of doses.
S. aureus: 0.25 μg/mL to 4.0 μg/mL S. aureus (methicillin resistant or MRSA): 1 μg/mL to 138 μg/mL S. epidermidis: ≤0.12 μg/mL to 6.25 μg/mL Although once described as narrow-spectrum, numerous studies have now shown that vancomycin decreases the levels of a wide spectrum of bacteria, including members of the Gram-negative Bacteroidota that are important in the human gut.
Sources: en.wikipedia.org
=== Names === Atomoxetine was originally known as tomoxetine. It was renamed to avoid medication errors, as the name may be confused with tamoxifen. In India, atomoxetine is sold under brand names including Axetra, Axepta, Attera, Tomoxetin, and Attentin. In Australia, Canada, Italy, Portugal, Romania, Spain, Switzerland, and the US, atomoxetine is sold under the brand name Strattera. In France, hospitals dispense atomoxetine under the brand name Strattera (it is not marketed in France). In the Czech Republic, it is sold under brand names including Mylan. In Poland, it is sold under the brand name Auroxetyn. In Indonesia, it is sold under the brand name Xenocy. In Iran, atomoxetine is sold under brand names including Stramox. In Brazil, it is sold under the brand name Atentah. In Turkey, it is sold under the brand names Attex, Setinox, and Atominex. In 2017, a generic version was approved in the United States.
=== Health === On May 18, 2025, Biden's office announced that he had been diagnosed with aggressive prostate cancer with bone metastasis during a routine physical examination. On May 30, Biden confirmed that he had begun treatment. On September 4, Biden's spokesperson confirmed that he had recently undergone Mohs surgery to remove skin cancer lesions from his forehead. The procedure followed a 2023 removal of a basal-cell carcinoma from his chest. On October 11, Biden's spokesperson confirmed that he was undergoing radiation and hormone therapies for his prostate cancer. On October 20, Biden completed a course of radiation therapy at Penn Medicine Radiation Oncology at the University of Pennsylvania. In August 2026, Hunter Biden said the cancer had "spread, metastasized into his bones and further" and was "very painful and it's very debilitating in many respects". In September 2026, Biden announced that the radiation treatment he received for prostate cancer last fall "worked as intended" and that doctors helped in disease control.
A 2020 study concluded that atypical antipsychotics are linked to cortical thinning and cognitive decline in the mid (20 months) to long-term. Use of antipsychotics is associated with reductions in brain tissue volumes, including white matter and cortical reduction, an effect which is dose-dependent and time-dependent. However, untreated psychosis is also associated with brain tissue volume reduction. A 2013 meta-analysis published in JAMA Psychiatry confirmed an association between cumulative antipsychotic exposure and progressive brain volume loss (cortical atrophy) in patients with schizophrenia. Despite a global reduction in brain volume noted, a recent controlled trial suggests that second generation antipsychotics combined with intensive psychosocial therapy may potentially prevent volume loss in the globus pallidus in first episode psychosis. A 2012 meta-analysis concluded that grey matter loss is greater in patients treated with first generation antipsychotics relative to those treated with atypicals, and hypothesized a protective effect of atypicals as one possible explanation. A second 2012 meta-analysis suggested that treatment with antipsychotics was associated with increased grey matter loss. Animal studies found that monkeys exposed to both first- and second-generation antipsychotics experience significant reduction in brain volume, resulting in an 8-11% reduction in brain volume with preserved neuron count and decreased glial cell count over a 17–27 month period.
== History and literature == The compound was discovered by Justus von Liebig and Friedrich Wöhler. It is one of the oldest named organic compounds. It was originally prepared in 1818 by Luigi Valentino Brugnatelli (1761-1818) and was named in 1838 by Wöhler and Liebig. The name "Alloxan" emerged from an amalgamation of the words "Allantoïn" and "Oxalsäure" (oxalic acid). The alloxan model of diabetes was first described in rabbits by Dunn, Sheehan, and McLetchie in 1943. The name is derived from allantoin, a product of uric acid excreted by the fetus into the allantois, and oxaluric acid derived from oxalic acid and urea, found in urine. Alloxan was used in the production of the purple dye murexide, discovered by Carl Wilhelm Scheele in 1776. Murexide is the product of the complex in-situ multistep reaction of alloxantin and gaseous ammonia. Murexide results from the condensation of the unisolated intermediate uramil with alloxan liberated during the course of the reaction.
As of 28 October, the number of US troops in the Southern Caribbean and Puerto Rico had expanded to 10,000, with about half in Puerto Rico and half on vessels. US military assets in the region are insufficient for an invasion. The forces included elements of the 160th Special Operations Aviation Regiment which provides helicopter aviation support for special operations forces. Venezuela's armed forces are estimated at 125,000 as of October 2025, with experts saying its military is "in shambles" according to The Wall Street Journal, which wrote on 17 October that Venezuela had issued a call to arms, and "cranked up its propaganda machine", announcing that the US wanted its oil wealth, as Venezuela was moving troops to the coast and prepared to "repel any invasion". With the 11 November arrival of USS Gerald R. Ford and its escorts to the USSOUTHCOM region, the US had about 15,000 personnel in the area, described by The Washington Post as "a stunning military presence in a region that historically has seen only one or two Navy vessels assisting the U.S. Coast Guard on routine drug-interdiction missions". Reuters reported on 2 November 2025 that: "The military buildup in the region is the largest unrelated to disaster relief since 1994, when the United States sent two aircraft carriers and more than 20,000 troops to Haiti" during Operation Uphold Democracy.
Sources: en.wikipedia.org
The shape of the ribosomal tunnel is irregular, and its size varies depending on the organism and cell type. Ribosomal tunnels in bacteria are generally longer and wider than those in the ribosomes of higher organisms. In bacteria, the tunnel length is approximately 9.2 nm, while in eukaryotes it is about 8.3 nm and the average radius of the ribosomal tunnel is on average 0.57 nm in bacteria and 0.51 nm in eukaryotes. The tunnel can accommodate a polypeptide consisting of around 40 to 60 amino acid residues. The tunnel walls are composed of rRNA and several ribosomal proteins. The tunnel is filled with water and ions, while small molecules such as ornithine may diffuse into it. The tunnel contains a constriction formed by loops of ribosomal proteins uL4 and uL22, which divide the tunnel space into an inner and an outer part (sometimes also referred to as the upper and lower parts). The inner portion near the catalytic site is approximately 3.5 nm long and accommodates a nascent polypeptide of 12 to 16 amino acid residues. There is a second constriction in the ribosomes of some eukaryotes that has implications for the regulation of short peptide synthesis. The outer part of the tunnel widens toward its opening and forms the so-called vestibule. The opening of the tunnel is flanked by the ribosomal proteins uL23, uL24, uL29 and uL32. In eukaryotes, also uL35, uL39e, or uL25. Ribosome-associated protein biogenesis factors such as the trigger factor or peptide deformylase bind to their vicinity.
=== Stress === Sustained stress can lead to high levels of circulating cortisol (regarded as one of the more important of the several "stress hormones"). Women show larger increases in cortisol than men when chronically stressed.
On 26 January 2016, having still not started a league match, Tottenham agreed a transfer fee with Newcastle United for Townsend, reportedly £12 million. Before the fee had been announced, Townsend had already tweeted a goodbye message, and stated "As soon as I knew of Newcastle's interest they were the only club I wanted to join...Two of the best positions you can play in football are centre-forward and left wing at Newcastle. I've got the chance. I could never turn that down. I can't wait to play my first game at St James' Park". The transfer was confirmed the following day, a five-and-a-half-year contract but with the club declining to disclose the fee. On signing, his new manager, Newcastle head coach Steve McClaren, said of Townsend that he is a "winger with an old-fashioned style. He can play on the right or the left, is two-footed, quick, very direct and loves taking on defenders and crossing the ball." According to Sky Sports, the transfer had been under negotiation for a week and Newcastle had initially wanted Townsend on loan, and then had a transfer offer of £10.5m rejected. Despite his debut for Newcastle being in a disappointing team performance in an away defeat, at the next match, his home debut, he was given a standing ovation after a Man of the Match performance which saw Newcastle climb out of the relegation places. His first goal for the club came in his third match, a shot from just outside the area, but it was just a 90th minute consolation goal in a 5–1 away defeat to Chelsea and the club was relegated to the Championship at the end of the season.
The first pathway begins with a P450 enzyme, ibogamine-10-hydroxylase (I10H), and methylation of noribogaine-10-Ο-methyltransferase (N10OMT) to produce (-)-voacangine. Polyneudridine aldehyde esterase-like 1 (PNAE1) and a spontaneous decarboxylation can convert (-)-voacangine to (-)-ibogaine. The second pathway consists of PNAE1 and the spontaneous decarboxylation occurring first to yield (-)-ibogamine, then the reaction of I10H-mediated hydroxylation and N10OMT-catalyzed O-methylation to produce (-)-ibogaine.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。